COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Thousands					3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2026	Mar. 27, 2026	Mar. 02, 2026	Nov. 12, 2025	Mar. 31, 2026	Mar. 31, 2025	Jun. 30, 2026	Dec. 31, 2025
Product Liability Contingency [Line Items]
Royalty percentage			2.00%
Net sales
License agreement description					(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro was obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses.
Milestone payments payable			$ 15,000
Non-US [Member] | Food and Drug Administration [Member]
Product Liability Contingency [Line Items]
Payment for milestone					$ 1,500
Phase I Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone					150
Item 1 And 2 [Member] | Phase II [Member]
Product Liability Contingency [Line Items]
Payment for milestone					250
Item 3 [Member] | Phase II Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone					500
Item 1, 2 and 3 [Member]
Product Liability Contingency [Line Items]
Payment for milestone					250
Net sales								$ 5,000
Item 4 [Member]
Product Liability Contingency [Line Items]
Payment for milestone					2,500
Net sales					50,000
Item 4 [Member] | Food and Drug Administration [Member]
Product Liability Contingency [Line Items]
Payment for milestone					1,500
Item 4 [Member] | Phase II Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone					250
Item 4 [Member] | Phase I Clinical Trial [Member]
Product Liability Contingency [Line Items]
Payment for milestone					150
Exclusive License Agreement [Member]
Product Liability Contingency [Line Items]
License fee					5
Annual maintenance fee					$ 10
Royalty percentage					3.75%
Exclusive License Agreement [Member] | Item 4 [Member]
Product Liability Contingency [Line Items]
License fee					$ 50
Annual maintenance fee					$ 10
Royalty percentage					4.25%
Minimum requirerment of capital	$ 500				$ 500
Patent product sales					0.50%
Exclusive License Agreement [Member] | Minimum [Member]
Product Liability Contingency [Line Items]
Patent protection costs					$ 9
Other non-royalty sublicense fees percentage					5.00%
Exclusive License Agreement [Member] | Minimum [Member] | Item 4 [Member]
Product Liability Contingency [Line Items]
Other non-royalty sublicense fees percentage					5.00%
Exclusive License Agreement [Member] | Maximum [Member]
Product Liability Contingency [Line Items]
Patent protection costs					$ 61
Other non-royalty sublicense fees percentage					35.00%
Exclusive License Agreement [Member] | Maximum [Member] | Item 4 [Member]
Product Liability Contingency [Line Items]
Other non-royalty sublicense fees percentage							35.00%
Enviro Cedars License Agreements [Member] | Item 1 And 2 [Member] | Phase III [Member]
Product Liability Contingency [Line Items]
Net sales					$ 100,000
Enviro Cedars License Agreements [Member] | Phase III Clinical Trial [Member]
Product Liability Contingency [Line Items]
Net sales					$ 50,000
Lonza Amendment [Member]
Product Liability Contingency [Line Items]
Payments for purchase of assets	$ 160	$ 2,000		$ 1,143